ASSESSMENT OF SERUM SCLEROSTIN LEVEL AS A BIOMARKER ASSOCIATED WITH BONE DISORDERS IN Β-THALASSEMIA PATIENTS IN AL- NAJAF CITY, IRAQ
Background: β-thalassemia is a blood disorder in which the body does not make hemoglobin normally. Aim: To assess serum sclerostin in female patients with beta-thalassemia and compare with the healthy controls and to predict its complication associated with the bone pathophysiology, for designed improvement the lifestyle goodliness for these patients. Material and methods: Sixty-nine female beta-thalassemia (βT) patients (54 βT major and 15 βT Intermedia), aged 8-40 years who dependent on transfused blood, and 20 healthy controls were evaluated serum sclerostin, and was examined the relationship with hematological parameters RBC, Hb, PCV, WBC, PLT, BMI, splenic status, iron, and ferritin levels. The information of beta-thalassemia patients was collected and records by the questioner. Results: A significantly increased serum sclerostin level (mean 26.80±0.91) pg/ml was showed in βT patients compared with the healthy controls (10.03±0.68, p smaller than 0.001) pg/ml. Furthermore, a significant decrease (p smaller than 0.05) of the sclerostin level was observed in β-thalassemia major compared to intermedia β-thalassemia patients. Serum sclerostin level revealed a significant increase in progress age; it is highest in the age group (30-40) year as compared with age group (8-18) and (19-29) year respectively. Sclerostin showed no associations with the RBC, Hb, PCV, and significantly positively correlated (p smaller than 0.05) with serum iron, ferritin levels, WBC, and PLT count. Significantly higher sclerostin levels in splenectomized and underweight groups were observed compared to unsplenectomized and normal-weight groups (p smaller than 0.05) of βT patients. Conclusions: Sclerostin plays an important role in beta-thalassemia patients and can serve as a biomarker associated with the bone pathophysiology and indicator to prevent the continuation of such serious diseases caused by iron overload in these patients.
Read ArticleNATURAL EXTRACTS AS A PROMISING SOLUTION FOR GRAM-POSITIVE ANTIBIOTIC RESISTANCE: A COMPREHENSIVE REVIEW
Background: Antibiotic resistance is currently one of the biggest problems in public health. Infectious diseases are the second human death cause, and the emergence of antimicrobial-resistant bacteria increases mortality and morbidity rates. There is a growing clinical need for the development of new antibiotics. In this line, WHO issued an alert about 12 bacteria with an urgent need to develop new antibiotics. Aims: This review aims to analyze the current knowledge of their antibacterial activity against the gram-positive pathogens listed by WHO and their extraction techniques. Methods: We systematically reviewed the literature in PubMed, searching publications describing the use of natural extracts as antibiotics over bacteria. The exclusion criteria consisted of limiting papers on natural extracts tested over the bacteria culture related to eleven selected bacteria, according to an alert issued by WHO in 2017, and seven plant extracts. Results: All the gram-positive bacteria present in the WHO alert have been treated, with different degrees of advance, with some of the plant extracts and plant-based compounds reviewed. Currently, they are in the preclinical stage. Edible herbs are more often used, as well as artemisia and wine byproducts. Discussion: Natural products based on plants have shown to be efficient in inhibiting bacterial growth, even in antibiotic-resistant strains. The classical extraction methods are still in use and have been improved with the available technology to improve efficiency and yield. Conclusions: Ongoing evidence shows that plant extracts and plant-based compounds are effective as antibacterial, with minimal effects on the host cell, a promising antibiotic source. Furthermore, they are sustainable, environmentally friendly, and renewable.
Read ArticleREVIEW ABOUT DIABETES MELLITUS AND URINARY TRACT INFECTIONS
Diabetes mellitus (DM) is a clinical disease correlated with a deficiency of insulin secretion or action.It is one of the leading causes of morbidity and mortality worldwide. The global burden of diabetes is rising dueto increasing obesity and population aging. Urinary tract infections (UTI) are common microbial infections knownto affect the different parts of the urinary tract accounting for major antibacterial drug consumption. About 150million UTI cases were diagnosed every year. Urinary tract infections are the most important and most commonsite of infections in a diabetic patient. Diabetic patients have been found to have a 5-fold frequency of acutepyelonephritis at autopsy than non-diabetics. Most of the urinary tract infections in patients with diabetes arerelatively asymptomatic. The presence of this syndrome predisposes to much more severe infections,particularly in patients with acute ketoacidosis, poor diabetic control, diabetic complications such as neuropathy,vasculopathy, and nephropathy. The Gram-negative aerobic bacilli are the large group of bacterial pathogensthat cause UTI with few species of Gram-positive bacteria. However, some fungi, parasites, and viruses havealso been reported to invade the urinary tract. Urinary tract infection affects women more than men due toseveral factors such as proximity of the genital tract to the urethra, anatomy of the female urethra, sexualactivity, menopause, and pregnancy. Other possible risk factors of UTI include allergy, obesity, diabetes, pasthistory of UTI, contraceptive use, catheter use, and family history.
Read Article